{"id":"NCT00530855","sponsor":"UCB Pharma","briefTitle":"Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures","officialTitle":"A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects With Partial-onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2007-09-18","resultsPosted":"2015-06-03","lastUpdate":"2018-07-18"},"enrollment":322,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Lacosamide","otherNames":["Vimpat"]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"}],"summary":"This open-label extension trial will assess the long-term use of Lacosamide monotherapy and safety of Lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in the conversion to monotherapy trial (SP902).","primaryOutcome":{"measure":"Percentage of Subjects on Lacosamide (LCM) Monotherapy at Any Time Between Visit 1 and End of Study","timeFrame":"From Visit 1 to End of Study (approximately 2 years)","effectByArm":[{"arm":"Lacosamide","deltaMin":292,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":108,"countries":["United States","Australia","Canada","Denmark","Germany","Italy","Poland","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":322},"commonTop":["Dizziness","Headache","Nausea","Upper respiratory tract infection","Fatigue"]}}